Physician

Akgun Ince, M.D.

According to 2025 Medicare claims, Akgun Ince, M.D. (NPI: 1053372334) practices rheumatology in the St. Louis, MO-IL market, with the plurality of this provider's patient population coming from St. Louis, MO. This provider's primary affiliated billing organization is ARTHRITIS CONSULTANTS INC. (NPI: 1770544066; TIN: 430947490) and primary practice location at 63141-6819. Ince is affiliated with the Caravan Health ACO 50 LLC (ACO ID: A5160) and IHCI ACO Midwest LLC (ACO ID: A5516), participating under the MSSP model.

Ince's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 338 traditional Medicare patients, billed 151,619 HCPCS/CPT codes, and received $2,102,044 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,977 prescription claims across 765 beneficiaries totaling $1,692,388 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 176 records totaling $50,608. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $839,350 to $1,692,388. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	566	83,556	$1,630,567
2016	603	84,087	$1,889,513
2017	564	96,236	$2,123,885
2018	542	92,159	$2,277,420
2019	573	119,377	$2,454,430
2020	456	123,145	$2,192,644
2021	448	105,595	$1,932,380
2022	501	169,920	$2,572,358
2023	435	172,804	$2,337,411
2024	338	151,619	$2,102,044

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	600	4,482	$839,350
2016	641	3,794	$855,715
2017	644	3,658	$845,626
2018	708	3,982	$805,754
2019	767	4,391	$979,724
2020	774	4,444	$853,441
2021	783	4,497	$997,277
2022	812	4,119	$1,282,690
2023	746	3,692	$1,471,302
2024	765	3,977	$1,692,388

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	215	341	$89
96413	Administration of chemotherapy into vein, 1 hour or less	74	457	$86
96415	Administration of chemotherapy into vein, each additional hour	72	501	$19
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	171	267	$12
36415	Insertion of needle into vein for collection of blood sample	133	470	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	62	2,128	$706,930
Enbrel Sureclick	Etanercept	33	924	$255,421
Enbrel	Etanercept	18	504	$140,171
Actemra Actpen	Tocilizumab	13	476	$81,655
Cosentyx Sensoready (2 Pens)	Secukinumab	12	336	$81,177

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	170	$3,598	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$47,010	UCB SA
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Akgun Ince, M.D.?

Tedicare shows public-source Medicare data for Akgun Ince, M.D. (NPI 1053372334), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Akgun Ince, M.D. have ACO affiliation data?

Akgun Ince, M.D. is shown with ACO affiliation data for Caravan Health ACO 50 LLC (MSSP, ACO ID A5160) and IHCI ACO Midwest LLC (MSSP, ACO ID A5516).

What billing organization is linked to Akgun Ince, M.D.?

Akgun Ince, M.D. is linked to ARTHRITIS CONSULTANTS INC. (billing NPI 1770544066) in the available physician profile data.

Does Akgun Ince, M.D. have Open Payments data?

Akgun Ince, M.D. has 176 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.